Evogene Aims for $79M in Net Proceeds in Planned US IPO | GenomeWeb

NEW YORK (GenomeWeb News) – Israeli plant genomics company Evogene said in an amended registration statement filed with the US Securities and Exchange Commission on Wednesday that it aims to raise $79 million in net proceeds through its initial public offering in the US.

Evogene said that it plans to offer 5 million shares of its common stock at a proposed maximum offering price of $17.16 per share. If the underwriters on the offering exercise their overallotment option, that figure would rise to $90 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.